Perillyl alcohol emulsion-based circular RNA delivery system, construction method and application

A circular RNA delivery system constructed by combining perillyl alcohol emulsion with charged lipids solves the problem of non-viral nanomedicine carriers being unable to target and deliver nucleic acid drugs in vivo, achieving the brain delivery of circular RNA, significantly upregulating circDYM gene expression, and alleviating depressive symptoms.

CN118924684APending Publication Date: 2024-11-12SOUTHEAST UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411323620.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-23
Publication Date
2024-11-12

Smart Images

  • Figure CN118924684A_ABST
    Figure CN118924684A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of biological medicines, and particularly relates to a circular RNA delivery system based on a perillyl alcohol emulsion, a construction method and application. The circular RNA delivery system comprises circular RNA, perillyl alcohol hydrophobic molecules and charged lipid, wherein the circular RNA delivery system comprises circular RNA, perillyl alcohol hydrophobic molecules and charged lipid; the mass ratio of the perillyl alcohol hydrophobic molecules in the circular RNA delivery system is 0-60%; and the mass ratio of the charged lipid is 5-30%. The perillyl alcohol nano-emulsion with the charged property provided by the invention can coat and deliver a circular RNA (Ribonucleic Acid) drug for circDYM target gene expression, and the drug is injected into a mouse for three times through nasal administration, so that the circDYM gene expression of the mouse brain is remarkably improved, and the depression-like behavior of the mouse is relieved. Meanwhile, the circDYM medicine for relieving the depression-like behavior provided by the invention can be prepared into a medicine together with one or more pharmaceutically acceptable auxiliary materials, and is applied to treatment of indications related to circDYM gene expression, such as cardiovascular diseases, neurodegenerative diseases, cancers, autoimmune diseases and the like.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the technical field of biomedicine, and in particular relates to a perillyl alcohol emulsion-based circular RNA delivery system, a construction method and an application thereof. Background Art

[0002] In recent years, many studies have demonstrated the feasibility and excellent clinical efficacy of non-viral nano-drug carriers in delivering nucleic acid drugs. However, although nucleic acid drugs can be efficiently encapsulated in vitro, the current non-viral nano-drug delivery technology is unknown for organ targeting and cannot effectively deliver nucleic acid drugs to the site of drug action in vivo. Many studies have shown that most unmodified or unoptimized non-viral nano-carriers and encapsulated nucleic acid drugs will be cleared by the mononuclear phagocyte system (MPS) in the body after administration, causing the drugs to accumulate in the liver and spleen, which are rich in macrophages. Repeated administration will have the risk of related organ damage and side effects. At the same time, when the target organ is the brain, most nano-drug delivery technologies have difficulty penetrating the blood-brain barrier to effectively release drugs into the brain microenvironment. Therefore, the current nucleic acid drug delivery technology for brain-targeted treatment of central nervous system diseases has not been fully developed.

[0003] Perillyl Alcohol (POH) is a natural monoterpene extracted from plants such as Perilla frutescens. Studies have shown that perillyl alcohol can increase the ability of drugs to pass through the blood-brain barrier by changing the structure and function of the blood-brain barrier. At the same time, perillyl alcohol can also be used in combination with nanocarrier systems to further improve the efficiency of drug delivery. This combination can utilize the multiple biological activities of perillyl alcohol to enhance the brain-targeted delivery of drugs. Although the single perillyl alcohol structure cannot become an effective drug carrier and delivery system, its hydrophobic properties suggest that perillyl alcohol can be combined with charged lipids or emulsifier components to prepare perillyl alcohol-based nanoemulsions to achieve brain drug delivery. Literature suggests that intervening in the expression of circular RNA (such as upregulating the expression of circDYM) can significantly alleviate the depressive-like behavior of mice, but there is currently a lack of brain delivery technology for circular RNA. Therefore, perillyl alcohol-based nanoemulsions can achieve brain delivery of circular RNA and can be used as a precise treatment for depression. Summary of the invention

[0004] In view of the deficiencies in the prior art, the present invention proposes a circular RNA delivery system based on perillyl alcohol emulsion, a construction method and an application.

[0005] The purpose of the present invention can be achieved through the following technical solutions:

[0006] A circular RNA delivery system based on perillyl alcohol emulsion, comprising circular RNA, perillyl alcohol hydrophobic molecules and charged lipids; the mass proportion of perillyl alcohol hydrophobic molecules in the circular RNA delivery system is 0-60%; the mass proportion of the charged lipids is 5-30%.

[0007] Furthermore, the charged lipid is a combination of two or more of DOTAP, SM-102, DSPC, cholesterol and PEG lipid.

[0008] Furthermore, the nitrogen-phosphorus ratio of the cationic or ionizable component to the circular RNA in the circular RNA delivery system is (3-10):1.

[0009] Furthermore, the sense strand sequence of the circular RNA is SEQ ID NO: 1, and the antisense strand sequence of the circular RNA is SEQ ID NO: 2.

[0010] A method for constructing a perillyl alcohol emulsion circular RNA delivery system, the method comprising the following steps:

[0011] S1, preparing a circular RNA buffer with a buffer solution;

[0012] S2, preparing charged lipids into a nanoemulsion mixture with anhydrous ethanol and perillyl alcohol;

[0013] S3, mixing the nanoemulsion mixture with a buffer to prepare an empty nanoemulsion;

[0014] S4. The empty nanoemulsion and circular RNA buffer are mixed at a nitrogen-phosphorus ratio of cationic or ionizable components to circular RNA of (3-10):1, and then the ethanol is removed, diluted and the pH is adjusted to obtain a circular RNA delivery system based on perillyl alcohol nanoemulsion.

[0015] Furthermore, the buffer in step S1 is a sodium acetate buffer, the sodium acetate concentration is 25 mM, the pH of the configured circular RNA buffer is 5.0, and the concentration of circular RNA is 0.2 mg / mL.

[0016] Furthermore, the total concentration of charged lipids in the nanoemulsion mixture prepared in step S2 is 8-10 mg / mL.

[0017] Furthermore, in step S3, the buffer solution is sodium acetate buffer solution, and the volume ratio of the nanoemulsion mixture to the buffer solution is 1:10.

[0018] Furthermore, the pH value after adjustment in step S4 is 6.5-7.4.

[0019] A pharmaceutical composition for up-regulating circular RNA gene expression, the pharmaceutical composition comprising the perillyl alcohol emulsion-based circular RNA delivery system.

[0020] Beneficial effects of the present invention:

[0021] 1. The present invention targets circular RNA (circDYM) that upregulates circDYM target gene expression, and injects mice with drugs three times through the nose, significantly upregulating the gene expression of circDYM in the mouse brain. Therefore, the perillyl alcohol nanoemulsion delivery system for delivering circDYM provided by the present invention can be used as a complex preparation of circular RNA drugs, and can be made into drugs with one or more pharmaceutically acceptable excipients, and used to treat cardiovascular diseases and indications related to circDYM gene expression.

[0022] 2. In some embodiments, the pharmaceutical composition of the present invention can be administered via nasal administration.

[0023] 3. In some embodiments, after the depression modeling of mice was established by lipopolysaccharide (LPS), the drug was injected 3 times through the nose. Within one week after the end of the administration, the brain, heart, liver, spleen, lung, and kidney were taken out for RT-qPCR, flow analysis, and WB detection. The results showed that the circDYM drug of the present invention can significantly upregulate the expression of circDYM gene in the whole body and brain of mice, relieve the depressive-like behavior of mice, improve neural plasticity, and reduce neuroinflammatory response, and it is statistically significant. The experimental results show that the circular RNA drug for upregulating the expression of the circDYM target gene is expected to be a drug for the treatment of depression. BRIEF DESCRIPTION OF THE DRAWINGS

[0024] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, for ordinary technicians in this field, other drawings can be obtained based on these drawings without paying any creative work.

[0025] Figure 1 The physicochemical characterization (particle size, potential, and coverage) of perillyl alcohol nanoemulsion (PANE) was carried out;

[0026] Figure 2 To verify the delivery efficiency and cytotoxicity of PANE-coated circDYM to mouse cells in vitro;

[0027] Figure 3 To verify the brain delivery efficiency and circDYM upregulation efficiency of PANE-coated circDYM in mice at the in vivo level;

[0028] Figure 4To verify the effect of SALNP-coated circDYM on the upregulation of circDYM in the mouse brain and the depressive-like behavior of mice at the in vivo level;

[0029] Figure 5 To detect the regulatory effects of PANE-coated circDYM on neuroplasticity proteins, pro-inflammatory factors, microglia and neurons in the mouse brain at the in vivo level.

[0030] Figure 6 H&E staining was used for pathological examination to detect the effects of intranasal delivery of PANE-coated circDYM on the major organs of mice. DETAILED DESCRIPTION

[0031] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0032] Example

[0033] 1. Validation of the cyclization interface of circDYM drugs

[0034] Sequencing analysis of the in vitro synthesized circDYM revealed that the synthesized circDYM was cyclized in the designated cyclization region. The primer information is shown in Table 1 .

[0035]

[0036] 2. Preparation process of PANE-coated circDYM

[0037] (1) circDYM was taken and prepared into a circDYM sodium acetate solution with a pH of 5.0, a circDYM concentration of 0.2 mg / mL, and a sodium acetate concentration of 25 mM using sodium acetate buffer (pH = 5.0);

[0038] (2) Take perillyl alcohol, DOTAP, DSPC, and Tween 80, and use anhydrous ethanol or perillyl alcohol to prepare a lipid ethanol solution with a total lipid concentration of 8-10 mg / mL; wherein, in terms of molar percentage, the lipid component contains 5% DOTAP and 3-10% DSPC. In terms of mass percentage, perillyl alcohol accounts for 0-60%, and Tween 80 accounts for 10-15%. 0.1 mL of the lipid ethanol solution is injected into 1 mL of sodium acetate buffer using a 1 mL BD Shurui insulin syringe to prepare an empty perillyl alcohol nanoemulsion (PANE). wherein DOTAP can be replaced by SM-102 and PANE prepared in different processes; Tween 80 can be replaced by PEG-DMG 2000 and PANE prepared in different processes.

[0039] (3) 0.2 mL of the circDYM sodium acetate solution prepared in step (1) was injected into 0.2 mL of the PANE prepared in step (2) using a 1 mL BD Shurui insulin syringe, and incubated under vortex stirring for 1 minute to obtain the PANE initial solution containing circDYM (PANE-circDYM). The above steps (1) to (3) can be repeated to obtain more PANE-circDYM;

[0040] If anhydrous ethanol is contained in the preparation process, the ethanol in PANE is removed by ultrafiltration at a centrifugal force of 13000 g using an ultrafiltration tube with a molecular weight cutoff of 100 kDa, and the circDYM concentration is adjusted to 0.1 mg / mL with denuclease water, and the pH is adjusted to 7.0 with 0.1 M sodium hydroxide or hydrochloric acid solution to obtain a PANE-circDYM suspension.

[0041] 3. Detection of brain delivery efficiency of PANE-circDYM

[0042] C57BL / 6 mice were divided into two groups, LNP-circDYM group and PANE-circDYM group, with 5 mice in each group. The LNP or PANE-encapsulated circDYM suspension prepared above was stained with DiR, and the C57BL / 6 mice were nasally administered with an injection dose of 0.06 mg / kg. 4, 12, and 24 hours after injection, the mice were anesthetized with isoflurane and the SALNP fluorescence intensity was observed with an IVIS Spectrum imaging instrument. After imaging, the mice were killed and the organs (brain, heart, liver, spleen, lung, and kidney) were taken for fluorescence imaging again.

[0043] 4. Verification of the upregulatory effect of PANE-circDYM on circDYM gene expression at the in vivo level

[0044] The PANE-circDYM suspension prepared above was administered intranasally to C57BL / 6 mice at a dose of 0.02 mg / kg, 0.06 mg / kg, and 0.18 mg / kg, once every other day, for a total of three times. The mice were killed on the fifth day after the administration, and the brain, liver, and blood were obtained for later use.

[0045] RNA extraction method (Trizol method)

[0046] The brain tissue and liver tissue were placed in grinding tubes and ground separately. When grinding, 0.5 mL of Trizol reagent was added for every 200 mg of organ tissue.

[0047] Take 100uL of the ground organ tissue fluid, add 900uL of Trizol reagent, leave at room temperature for 10 minutes, then add 0.2mL of chloroform, mix thoroughly and leave on ice for 10 minutes to completely dissociate the nucleoprotein complex;

[0048] Centrifuge at 12000 rpm for 15 min at 4°C. During the centrifugation, take a new EP tube, add 500 μL of isopropanol, and pre-cool on ice;

[0049] After centrifugation, the upper aqueous phase (about 500 μL) was transferred to the above new EP tube containing 500 μL isopropanol and placed on ice for 10 min;

[0050] Centrifugation, 12000 rpm, 10 min;

[0051] Remove the supernatant and wash the RNA pellet once with 1 mL of 75% ethanol;

[0052] Centrifuge at 12000rpm for 5 minutes; remove the supernatant and air-dry or vacuum-dry the RNA precipitate for 5-10 minutes;

[0053] Dissolve the RNA in 30-50 μL of DEPC-treated deionized water (add water according to the amount of RNA precipitate);

[0054] NanoDrop1000 was used to determine the concentration and purity of total RNA samples.

[0055] Reverse transcription

[0056] The kit used was Novozymes HiScript Q RT SuperMix for qPCR (+gDNAwiper)

[0057] Genomic DNA removal

[0058] Prepare the following mixture in an RNase-free centrifuge tube:

[0059] <![CDATA[RNase-freeddH2O]]> 12–(Total RNA Template) 4xgDNAWiperMix 4uL Total RNA template 400 / RNA concentration

[0060] Mix by gently pipetting.

[0061] Reaction procedure: incubate at 42°C for 2 minutes.

[0062] cDNA synthesis

[0063] Prepare the following mixture in an RNase-free centrifuge tube:

[0064] The mixed solution obtained in step (1) 16uL 5×qRTSuperMixII 4uL

[0065] Mix by gently pipetting.

[0066] Reaction program: incubate at 50°C for 15 minutes and 85°C for 2 minutes to inactivate the reverse transcriptase.

[0067] Quantitative PCR

[0068] Prepare reagents: 2×AceQ qPCR SYBR Green MasterMix, DEPC-treated water, cDNA template, circRNA upstream and downstream primers.

[0069] Instrument: QuantStudioTM 5 System (272531287).

[0070] Prepare reaction solution: Prepare the reaction solution according to the table below.

[0071]

[0072]

[0073] Real-time qPCR amplification was performed according to the reaction conditions in the table below.

[0074] step set up Keeping Status 95°C, 5 min PCR state, cooling speed 1.6℃ per second 95℃, 10 sec 60℃, 30 seconds Melting curve stage 95℃, 15 seconds 60℃, 60 seconds 95℃, 15 seconds 72°C, 1 minute Reading value

[0075] After the reaction, the ΔCt method was used to record the Ct value of the sample, and the absolute copy number of the sample was calculated according to the standard curve of the synthetic circRNA. Absolute qPCR was performed to estimate the copy number of circDYM in the sample. Using fluorescent quantitative PCR technology, the plasmids of different concentrations were plotted in multiples of 10 to draw a standard curve. The copy number of the standard compound was calculated as follows: Copy number (copy / μL) = 6.02×10 23 ×Plasmid concentration (ng / μL)×10 -9 / [(vector molecular weight + insert molecular weight) × 660] (g / mol). The equations of the amplification curve and the standard curve are: Y = aX + b [the logarithmic value of the initial amplification copy number 10 is the horizontal axis (X), and the corresponding cycle number is the vertical axis (Y)]. The Ct value of the circRNA is calculated to any unit using the linear equation of the plasmid standard to draw a conclusion on the circRNA copy number. The results are shown in the figure. As can be seen from the figure, PANE-circDYM can successfully upregulate the expression of circDYM in the mouse brain.

[0076] 5. Verification of the therapeutic effect of PANE-circDYM on depression at the in vivo level

[0077] LPS depression model was established in mice. Healthy mice were intraperitoneally injected with 1 mg / kg LPS every day for 5 consecutive days. Depressed mice were screened for drug treatment based on behavioral tests. Behavioral tests of LPS depression model mice were carried out in a quiet room under low-intensity light between 9:00 and 17:00, and behavioral scores were performed by the same experimenter. Mice were placed in the room to adapt for at least 3 hours before the test. Behavioral tests were completed by analyzing images using the Plexon software system (Plexon Inc, Dallas, TX, USA). Specific test items included: Sucrose preference test (SPT), tail suspension test (TST), open field test (OFT) and forced swimming test (FST).

[0078] The C57BL / 6 depressed mice were divided into 6 groups (11 mice in each group), namely, saline group, empty PANE group, PANE-circDYM (0.02 mg / kg) group, PANE-circDYM (0.06 mg / kg) group, PANE-circDYM (0.18 mg / kg) group, and fluoxetine group (20 mg / kg intraperitoneal injection). The frequency of administration was once every 2 days, for a total of three times. The above behavioral tests were performed again 5 days after the end of treatment to verify the alleviating effect of PANE-circDYM on depressive-like symptoms.

[0079] The results are shown in the figure.

[0080] As can be seen from the figure, PANE-circDYM has a significant improvement on the depressive-like behavior of mice in the 0.02-0.18 mg / kg dosage group, and the improvement is statistically significant.

[0081] In the description of this specification, the description with reference to the terms "one embodiment", "example", "specific example", etc. means that the specific features, structures, materials or characteristics described in conjunction with the embodiment or example are included in at least one embodiment or example of the present invention. In this specification, the schematic representation of the above terms does not necessarily refer to the same embodiment or example. Moreover, the specific features, structures, materials or characteristics described can be combined in any one or more embodiments or examples in a suitable manner.

[0082] The above shows and describes the basic principles, main features and advantages of the present invention. Those skilled in the art should understand that the present invention is not limited to the above embodiments, and the above embodiments and descriptions are only for explaining the principles of the present invention. Without departing from the spirit and scope of the present invention, the present invention may have various changes and improvements, and these changes and improvements all fall within the scope of the present invention to be protected.

[0083] In the description of this specification, the description with reference to the terms "one embodiment", "example", "specific example", etc. means that the specific features, structures, materials or characteristics described in conjunction with the embodiment or example are included in at least one embodiment or example of the present invention. In this specification, the schematic representation of the above terms does not necessarily refer to the same embodiment or example. Moreover, the specific features, structures, materials or characteristics described can be combined in any one or more embodiments or examples in a suitable manner.

[0084] The above shows and describes the basic principles, main features and advantages of the present invention. Those skilled in the art should understand that the present invention is not limited to the above embodiments, and the above embodiments and descriptions are only for explaining the principles of the present invention. Without departing from the spirit and scope of the present invention, the present invention may have various changes and improvements, and these changes and improvements all fall within the scope of the present invention to be protected.

Claims

1. A circular RNA delivery system based on perillyl alcohol emulsion, characterized in that: The circular RNA delivery system comprises circular RNA, perillyl alcohol hydrophobic molecules and charged lipids; the mass proportion of perillyl alcohol hydrophobic molecules in the circular RNA delivery system is 0-60%; the mass proportion of the charged lipids is 5-30%.

2. A perillyl alcohol emulsion circular RNA delivery system according to claim 1, characterized in that: The charged lipids are a combination of two or more of DOTAP, SM-102, DSPC, cholesterol and PEG lipids.

3. A perillyl alcohol emulsion circular RNA delivery system according to claim 1, characterized in that: The nitrogen-phosphorus ratio of the cationic or ionizable component to the circular RNA in the circular RNA delivery system is (3-10):

1.

4. A perillyl alcohol emulsion circular RNA delivery system according to claim 1, characterized in that: The sense strand sequence of the circular RNA is SEQ ID NO: 1, and the antisense strand sequence of the circular RNA is SEQ ID NO:

2.

5. A method for constructing a perillyl alcohol emulsion circular RNA delivery system, characterized in that: The construction method comprises the following steps: S1, preparing a circular RNA buffer with a buffer solution; S2, preparing charged lipids into a nanoemulsion mixture with anhydrous ethanol and perillyl alcohol; S3, mixing the nanoemulsion mixture with a buffer to prepare an empty nanoemulsion; S4. The empty nanoemulsion and circular RNA buffer are mixed at a nitrogen-phosphorus ratio of cationic or ionizable components to circular RNA of (3-10):1, and then the ethanol is removed, diluted and the pH is adjusted to obtain a circular RNA delivery system based on perillyl alcohol nanoemulsion.

6. The method for constructing a perillyl alcohol emulsion circular RNA delivery system according to claim 5, characterized in that: The buffer in step S1 is a sodium acetate buffer, the sodium acetate concentration is 25 mM, the pH of the configured circular RNA buffer is 5.0, and the concentration of circular RNA is 0.2 mg / mL.

7. The method for constructing a perillyl alcohol emulsion circular RNA delivery system according to claim 5, characterized in that: The total concentration of charged lipids in the nanoemulsion mixture prepared in step S2 is 8-10 mg / mL.

8. The method for constructing a perillyl alcohol emulsion circular RNA delivery system according to claim 5, characterized in that: The buffer in step S3 is sodium acetate buffer, and the volume ratio of the nanoemulsion mixture to the buffer is 1:

10.

9. The method for constructing a perillyl alcohol emulsion circular RNA delivery system according to claim 5, characterized in that: The pH value after adjustment in step S4 is 6.5 to 7.

4.

10. A pharmaceutical composition for upregulating circular RNA gene expression, characterized in that: The pharmaceutical composition comprises the circular RNA delivery system based on perillyl alcohol nanoemulsion according to any one of claims 1 to 4.